Puma Plummets On Another Neratinib NDA Delay

Puma Biotechnology Inc. fell 21.1% to close at $27.92 per share on March 29 after it revealed a second major delay for the company's new drug application (NDA) submission to the US FDA for neratinib as an extended adjuvant treatment for early-stage HER2-positive breast cancer.